Table 2.
Laboratory and clinical outcomes during and seven days after clindamycin therapy. Values given are odds ratios and 95% confidence interval estimates.
| Continuous | Quartile 1 | Quartile 2 | Quartile 3 | Quartile 4 | |
|---|---|---|---|---|---|
| Laboratory adverse event | |||||
| AUCcum | 1.01 (0.98–1.03) | Ref | 0.77 (0.60–0.98) | 0.83 (0.63–1.08) | 1.05 (0.75–1.47) |
| Maximum Cmax | 1.02 (0.99–1.05) | Ref | 0.97 (0.78–1.21) | 1.04 (0.84–1.30) | 1.15 (0.92–1.44) |
| Sepsis | |||||
| AUCcum | 0.99 (0.95–1.03) | Ref | 0.82 (0.56–1.21) | 0.60 (0.39–0.91) | 0.56 (0.34–0.93) |
| Maximum Cmax | 0.99 (0.94–1.04) | Ref | 0.73 (0.50–1.06) | 0.80 (0.55–1.17) | 0.83 (0.57–1.20) |
| NEC | |||||
| AUCcum | 1.00 (0.95–1.04) | Ref | 1.40 (0.82–2.40) | 1.36 (0.78–2.37) | 1.95 (1.04–3.63) |
| Maximum Cmax | 1.05 (1.00–1.10) | Ref | 1.33 (0.84–2.09) | 1.23 (0.77–1.96) | 1.52 (0.96–2.42) |
| Intestinal perforation | |||||
| AUCcum | 0.97 (0.91–1.04) | Ref | 1.45 (0.48–4.42) | 2.17 (0.76–6.19) | 2.23 (0.72–6.91) |
| Maximum Cmax | 0.99 (0.89–1.10) | Ref | 0.64 (0.30–1.39) | 0.88 (0.42–1.83) | 0.74 (0.34–1.59) |
| Seizures | |||||
| AUCcum | 1.02 (0.95–1.10) | Ref | 0.96 (0.44–2.07) | 0.88 (0.39–2.02) | 1.02 (0.38–2.73) |
| Maximum Cmax | 1.02 (0.94–1.12) | Ref | 0.62 (0.29–1.31) | 0.67 (0.32–1.38) | 1.07 (0.56–2.06) |
| Stricture | |||||
| AUCcum | 0.84 (0.63–1.13) | Ref | 6.87 (0.14–346.96) | 8.60 (0.31–241.72) | - |
| Maximum Cmax | 0.73 (0.39–1.35) | Ref | 0.31 (0.03–3.49) | - | 0.35 (0.03–4.18) |
AUCcum indicates total area under the curve during entire course (mcg*h/100mL); Cmax: maximum concentration (mcg/mL)